文献速递乳腺癌

TBCRC 030:三阴性乳腺癌术前顺铂对比紫杉醇的II期研究及HRD生物标志物评估

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
PubMed 文献 · Ann Oncol · 2020-08-13

该前瞻性II期研究将gBRCA1/2野生型/未知的I-III期三阴性乳腺癌患者随机分配接受12周术前顺铂或紫杉醇治疗,旨在检测HRD评分与病理缓解(RCB-0/1)的关联。

要点

  • HRD阳性与顺铂或紫杉醇的RCB-0/1缓解均无显著关联。
  • 顺铂与紫杉醇在术前治疗中表现出相似的病理缓解率。
  • gBRCA1/2野生型/未知TNBC中HRD不能预测病理缓解。

核心结论

  • 在三阴性乳腺癌术前治疗中,HRD评分不能预测顺铂或紫杉醇的病理缓解。
  • 肿瘤对术前紫杉醇或顺铂化疗的缓解程度相似。

研究设计与样本

  • 前瞻性II期随机研究,纳入gBRCA1/2野生型/未知的I-III期三阴性乳腺癌患者。
  • 患者接受12周术前顺铂或紫杉醇单药化疗,基线组织行HRD检测(评分≥33为阳性)。

主要发现

  • 104例(74.8%)肿瘤有HRD结果,其中74例(71.1%)为HRD阳性。
  • 顺铂组RCB-0/1率为26.4%,紫杉醇组为22.3%。
  • HRD阳性与顺铂组RCB-0/1的OR为2.22(95%CI:0.39-23.68),与紫杉醇组的OR为0.90(95%CI:0.19-4.95)。
  • 未观察到HRD与化疗病理缓解之间的交互作用证据。

临床怎么用

  • 对于gBRCA1/2野生型/未知的I-III期三阴性乳腺癌,HRD评分不宜用于优先选择顺铂或紫杉醇。
  • 顺铂和紫杉醇均可作为术前化疗选择,缓解率相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. The homologous recombination deficiency (HRD) assay (Myriad Genetics, Inc.) detects impaired double-strand DNA break repair and may identify patients with BRCA1/2-proficient tumors that are sensitive to DNA-targeting therapy. The primary objective of TBCRC 030 was to detect an association of HRD with pathologic response [residual cancer burden (RCB)-0/1] to single-agent cisplatin or paclitaxel. PATIENTS AND METHODS: This prospective phase II study enrolled patients with germline BRCA1/2 wild-type/unknown stage I-III TNBC in a 12-week randomized study of preoperative cisplatin or paclitaxel. The HRD assay was carried out on baseline tissue; positive HRD was defined as a score ≥33. Crossover to an alternative chemotherapy was offered if there was inadequate response. RESULTS: One hundred and thirty-nine patients were evaluable for response, including 88 (63.3%) who had surgery at 12 weeks and 51 (36.7%) who crossed over to an alternative provider-selected preoperative chemotherapy regimen due to inadequate clinical response. HRD results were available for 104 tumors (74.8%) and 74 (71.1%) were HRD positive. The RCB-0/1 rate was 26.4% with cisplatin and 22.3% with paclitaxel. No significant association was observed between HRD score and RCB response to either cisplatin [odds ratio (OR) for RCB-0/1 if HRD positive 2.22 (95% CI: 0.39-23.68)] or paclitaxel [OR for RCB-0/1 if HRD positive 0.90 (95% CI: 0.19-4.95)]. There was no evidence of an interaction between HRD and pathologic response to chemotherapy. CONCLUSIONS: In this prospective preoperative trial in TNBC, HRD was not predictive of pathologic response. Tumors were similarly responsive to preoperative paclitaxel or cisplatin chemotherapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Mayer EL, Abramson V, Jankowitz R, et al. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Ann Oncol. 2020. PMID: 32798689. doi:10.1016/j.annonc.2020.08.2064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。